Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection

Boer, W. A. De; Driessen, W. M. M.; Jansz, A; Tytgat, G. N. J.

doi:10.1016/s0140-6736(95)92962-2

Cited by 206 publications

(143 citation statements)

References 19 publications

Supporting

Mentioning

138

Contrasting

Order By: Relevance

“…Patients were male or female, aged 18-75 years, suffering from dyspepsia with or without ulcer disease, and testing positive for H. pylori by 13 C-urea breath test. This positive result had to be confirmed by histology and ⁄ or culture of pre-treatment biopsies of the gastric mucosa.…”

Section: Patientsmentioning

confidence: 99%

“…Sensitivity to metronidazole was also assessed from these biopsies. 13 C-urea breath test and endoscopy with biopsies (three from the antrum and two from the corpus). One biopsy from the antrum was used for on-site rapid urease test, one from the antrum and one from the corpus were processed to histology, and one from the antrum and one from the corpus were used for culture and to assess metronidazole resistance.…”

Section: Patientsmentioning

confidence: 99%

“…Results from trials have confirmed that the addition of a proton pump inhibitor to bismuth-based triple therapy increases the eradication rate, even in metronidazole-resistant H. pylori strains. [13][14][15] However, in order to comply with this quadruple therapy, patients must take tablets and capsules from four different bottles, some four times a day and some twice or once a day. A new single-triple capsule containing bismuth biskalcitrate, metronidazole and tetracycline, administered with a proton pump inhibitor, was investigated in this study.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of single‐triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study

O’Moráin¹,

Borody²,

Farley³

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: The high prevalence of Helicobacter pylori resistance to metronidazole demands treatments more effective than standard bismuth-based triple therapy against these strains. Aim: To evaluate the H. pylori eradication rate in both metronidazole-sensitive and -resistant strains following quadruple therapy using single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole. Methods: One hundred and seventy valid patients with duodenal ulcer, gastric ulcer or non-ulcer dyspepsia were treated in eight centres located in five countries. H. pylori was confirmed at baseline using 13 C-urea breath test, histology and ⁄ or culture. Patients received three single-triple capsules q.i.d. and omeprazole,

show abstract

Section: Patientsmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of single‐triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study

O’Moráin¹,

Borody²,

Farley³

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…The ef®cacy of bismuth-based triple therapy is improved by the addition of a proton pump inhibitor, thereby turning it into quadruple therapy. 3,4,8 This allows the exploration of shorter treatments. Furthermore this addition improves the side-effect pro®le.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore this addition improves the side-effect pro®le. 8 Recently W. A. de Boer showed that a 4-day quadruple therapy with either omeprazole 3 or lansoprazole 4 as a proton pump inhibitor was very effective and well tolerated. Two-day quadruple therapy is only moderately effective, thus suggesting that shortening the regimen beyond 4 days is not useful.…”

Section: Discussionmentioning

confidence: 99%

Four‐day quadruple therapy as a routine treatment for Helicobacter pylori infection

Boer

Siem

1997

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: H. pylori eradication usually involves treatment with three or four drugs for at least 7 days. Possible advantages of short treatment regimens are better patient compliance and tolerability, and less adverse effects. Recently two reports have shown a cure rate of > 90% using a 4‐day quadruple therapy.Aim:To confirm these data and to evaluate the efficacy and tolerability of 4‐day quadruple therapy in a single centre.Methods:Thirty‐eight consecutive patients with non‐ulcer dyspepsia or peptic ulcer disease, and proven H. pylori infection, received 4 days of quadruple therapy (bismuth, tetracycline, metronidazole, lansoprazole). At least 6 weeks after treatment, endoscopy was repeated with six biopsies of antrum and corpus for histology and culture.Results:The intention‐to‐treat cure rate was 34/38 (89.5%, 95% CI: 79.7–99.2%). In the per protocol analysis the cure rate was 34/37 (91.9%, 95% CI: 83.1–100%). Primary metronidazole resistance was observed in two patients; both were cured. Metronidazole resistance induction was observed in one patient in whom therapy failed. The treatment was generally well tolerated.Conclusion:Routine use of 4‐day quadruple anti‐H. pylori treatment is effective and well tolerated.

show abstract

Treatment of Helicobacter pylori infection

Boer¹

1995

Archives of Internal Medicine

View full text Add to dashboard Cite

The bacterium Helicobacter pylori can infect the stomach during childhood and cause lifelong chronic gastritis, which can lead to peptic ulcer disease. Curing H pylori infection cures ulcer disease. 1-5 And since reinfection in adults is extremely rare, 6 adequate treatment permanently cures this former chronic recurrent, serious disease. If ulcers do not recur neither do ulcer perforation or bleeding; quality of life increases, 7 sick leave decreases, and less money is spent on visiting the doctor and drugs. Antibiotic resistance needs to be taken into account when designing treatment for H pylori infection. 8 Over the past decade many different therapies were promoted and recommendations changed rapidly. Most doctors lost track, and a great variety of treatments is being used. 9 In this article we will try to provide a basic framework on which treatment can be based. Methods This article is based largely on our experience in treating H pylori infection. We base our recommendations on basic bacteriological principles and on a regularly updated in-house computer database that contains the results of all published therapeutic studies.

show abstract

Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection

Cited by 206 publications

References 19 publications

Efficacy and safety of single‐triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study

Efficacy and safety of single‐triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study

Four‐day quadruple therapy as a routine treatment for Helicobacter pylori infection

Treatment of Helicobacter pylori infection

Contact Info

Product

Resources

About